Etodolac
- Generic Name
- Etodolac
- Brand Names
- Lodine
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO3
- CAS Number
- 41340-25-4
- Unique Ingredient Identifier
- 2M36281008
- Background
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
- Indication
For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.
- Associated Conditions
- Acute Pain, Chronic Back Pain, Extra-Articular Rheumatism, Juvenile Idiopathic Arthritis (JIA), Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Rheumatoid Arthritis, Spinal Disorders
- Associated Therapies
- -
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
- Conditions
- Stage III Ovary CancerOvarian CarcinomaFallopian Tube CancerOvarian CancerStage III Ovarian CancerStage IV Ovarian CancerStage II Fallopian Tube CancerStage III Fallopian Tube CancerStage II Ovary CancerStage IV Ovary Cancer
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT05429970
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
- Conditions
- Pain, Acute
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Apsen Farmaceutica S.A.
- Target Recruit Count
- 140
- Registration Number
- NCT03127592
- Locations
- 🇧🇷
Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil
Etodolac and Post-bleaching Sensitivity
- Conditions
- Medicaments Substances in Therapeutic Use
- Interventions
- Drug: PlaceboDrug: Etodolac
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Flavia Pardo Salata Nahsan
- Target Recruit Count
- 50
- Registration Number
- NCT02881619
Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT01749228
- Locations
- 🇮🇳
Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India
Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT01746719
- Locations
- 🇮🇳
Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India
MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains
- Conditions
- Ankle Sprains
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- MEDRx USA, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT01198834
A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 616
- Registration Number
- NCT01118572
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.